Clinical Trials Logo

Colon Cancer Liver Metastasis clinical trials

View clinical trials related to Colon Cancer Liver Metastasis.

Filter by:

NCT ID: NCT05293041 Recruiting - Clinical trials for Inflammatory Response

Argipressin's Influence on Blood Loss During Hepatic Resection

ARG-01
Start date: March 27, 2022
Phase: Phase 4
Study type: Interventional

Infusion of Argipressin during hepatic resection surgery may reduce blood loss. It may also reduce transfusion requirements, and mitigate the perioperative inflammatory response compared to placebo. Subjects will be randomized to infusion of Argipressin or placebo during surgery. Blood loss, transfusion requirements, surgical data including length of stay in hsopital, inflammatory markers and markers of renal- intestinal- and cardiac injury will be assessed.

NCT ID: NCT04682665 Recruiting - Clinical trials for Colon Cancer Liver Metastasis

Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases

Start date: September 16, 2021
Phase:
Study type: Observational

A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop disease recurrence and die from the disease. The EMT2 study (NCT03428477) is a clinical trial of the omega-3 fatty acid EPA, investigating whether patients who EPA ethyl ester remain free of disease recurrence for longer than those taking placebo. Recent data suggest that the anti-cancer effect of EPA may result from changes to the microbiota (gut bacteria) which lead to an improved anti-cancer response by the immune system. This study will collect biospecimens (stool, urine, blood, tumour tissue) from participants in the EMT2 trial in order to interrogate the microbiome and immune mechanisms associated with EPA treatment, in relation to participant survival. Insights from this study will identify those most likely to benefit from treatment, leading to more targeted, personalised use of EPA.

NCT ID: NCT04668872 Recruiting - Colorectal Cancer Clinical Trials

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Start date: December 7, 2020
Phase:
Study type: Observational

The purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure. This research may improve the way that radioembolization is performed, which could help people whose cancer has spread to the liver. The research may also provide information about how tumors respond to radioembolization.

NCT ID: NCT03415126 Completed - Cancer Clinical Trials

A Study of ASN007 in Patients With Advanced Solid Tumors

Start date: January 19, 2018
Phase: Phase 1
Study type: Interventional

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

NCT ID: NCT03370198 Terminated - Clinical trials for Colon Cancer Liver Metastasis

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

LINK
Start date: October 11, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases. The trial will test three dose levels (dose escalation). At each dose, the patients will receive three successive hepatic transarterial administrations, two weeks apart, of NKR-2 cells. The study will enroll up to 18 patients.

NCT ID: NCT03310008 Active, not recruiting - Clinical trials for Colon Cancer Liver Metastasis

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases

SHRINK
Start date: August 7, 2017
Phase: Phase 1
Study type: Interventional

SHRINK (Standard cHemotherapy Regimen and Immunotherapy with NKR-2) is an open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells administered concurrently with a standard chemotherapy treatment (FOLFOX) in potentially resectable liver metastases from colorectal cancer. The trial will test three dose levels. At each dose, the patients will receive three successive administrations, two weeks apart, NKR-2 cells. The study will enroll up to 36 patients (dose escalation and expansion phases).

NCT ID: NCT03175016 Recruiting - Clinical trials for Colon Cancer Liver Metastasis

Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer

DEBIRI-CRLM
Start date: June 20, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicentre, open labeled, single arm study to determine effectiveness and safety of chemoembolization with Irinotecan-Eluting Bead(DEBIRI) in the treatment of unresectable liver metastases in patients with colorectal cancer after chemotherapy failure.

NCT ID: NCT02781935 Completed - Colorectal Cancer Clinical Trials

Diffusion-Weighted MRI for Liver Metastasis

DREAM
Start date: November 2016
Phase:
Study type: Observational

The DREAM study will assess the diagnostic accuracy of diffusion-weighted MRI in combination with other imaging modalities (multiparametric MRI and CT Scan) in determining the true status of disappearing liver metastasis (DLM) detected after conversion systemic therapy for unresectable or borderline resectable colorectal liver metastasis (CRLM).

NCT ID: NCT02631564 Recruiting - Clinical trials for Colon Cancer Liver Metastasis

Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis

Start date: June 2015
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to observe whether hepatic infusion by oxaliplatin, irinotecan and raltitrexed with or without embolization by lipiodol or microspheres are effective in the treatment of refratory liver metastasis from colorectal cancer.

NCT ID: NCT02557490 Recruiting - Clinical trials for Colon Cancer Liver Metastasis

Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases

Start date: January 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study was a randomized controlled trial to compare the effect of oxaliplatin and raltitrexed treatment of colorectal cancer with liver metastases by TACE hepatic artery infusion